The Best FDA Decision On Peptide Authorization Isn’t Yes Or No
The Best FDA Decision On Peptide Authorization Isn't Yes Or No The Food and Drug Administration's approach to regulating therapeutic peptides has reached an inflection point, and according to a recent analysis published by Forbes, the most consequential path forward for the agency may not be a simp...
Read Full StoryRecent Regulatory News
Phoenix doctor urges caution as FDA moves to regulate popular peptides
Phoenix Doctor Urges Caution as FDA Moves to Regulate Popular Peptides A Phoenix-based physician is warning consumers to exercise caution amid growing regulatory scrutiny of peptide therapies, as the...
FDA issues warning letters to five unapproved GLP-1 websites
FDA Issues Warning Letters to Five Unapproved GLP-1 Websites The U.S. Food and Drug Administration has issued warning letters to five websites for allegedly marketing unapproved versions of GLP-1 rec...
FDA cracks down on online black market for weight loss peptides
FDA Targets Illicit Online Sales of Weight Loss Peptides Amid Surging Demand The U.S. Food and Drug Administration is intensifying scrutiny of an expanding online black market for weight loss peptide...
Aurobindo Pharma’s Auropeptides US FDA Inspection Ends With One Finding
Aurobindo Pharma's Peptide Manufacturing Unit Clears FDA Inspection With Single Observation Aurobindo Pharma's specialized peptide manufacturing subsidiary, Auropeptides, has concluded a US Food and ...
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Eli Lilly Files Suit Against Six Firms Over Unauthorized Retatrutide Sales Eli Lilly and Company has filed lawsuits against six companies it accuses of illegally manufacturing, marketing, and selling...